Exciting Growth Prospects Ahead for Iovance Biotherapeutics and Novavax

Iovance Biotherapeutics

Iovance Biotherapeutics recently gained accelerated approval for its groundbreaking cancer-fighting product, Amtagvi. This innovative therapy marks a significant milestone for the company and could revolutionize cancer treatment.

Key Points:

• Iovance's Amtagvi therapy receives FDA approval for advanced melanoma
• Wall Street predicts 120% stock price increase in the next 12 months

Novavax

Despite recent challenges, Novavax is making strides in cost-cutting and vaccine development. With potential market expansion strategies in place, Novavax aims for a strong rebound in the coming year.

Key Points:

1. Novavax pursues significant growth opportunities with new market approaches
2. Wall Street forecasts a 295% surge in stock price over the next year